SEC Form 4 · accession 0001209191-15-006252

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jan 21, 2015

Accepted (ET)

Jan 23, 2015 · 5:12 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jan 21, 2015	M	4,800	$10.41	A	343,695	D
Common Stock	Jan 21, 2015	M	1,300	$17.16	A	344,995	D
Common Stock	Jan 21, 2015	M	4,400	$35.64	A	349,395	D
Common Stock^F2,F3	Jan 21, 2015	S	6,800	$124.85	D	342,595	D
Common Stock^F3,F4	Jan 21, 2015	S	3,700	$125.50	D	338,895	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock^F5	holding	—	—		—	172,589	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F6	$10.41	Jan 21, 2015	M	4,800	D	—	Feb 2, 2015	Common Stock	4,800	4,988	D
Stock Option (right to buy)^F6	$17.16	Jan 21, 2015	M	1,300	D	—	Jul 19, 2015	Common Stock	1,300	33,000	D
Stock Option (right to buy)^F6	$35.64	Jan 21, 2015	M	4,400	D	—	Feb 1, 2016	Common Stock	4,400	534,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $124.85 (range $124.28 to $125.26).
F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $125.50 (range $125.28 to $125.91).
F5Common stock held in grantor retained annuity trusts.
F6Fully vested.